{"id":50265,"date":"2022-10-31T13:02:49","date_gmt":"2022-10-31T12:02:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/"},"modified":"2022-10-31T13:02:49","modified_gmt":"2022-10-31T12:02:49","slug":"cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/","title":{"rendered":"Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer\u2019s Disease at 2022 CTAD Conference"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#CTAD2022<\/a>—Cognito Therapeutics<\/a>, a clinical-stage company pioneering disease-modifying therapeutic interventions for neurodegenerative diseases, announced today it has been selected to present clinical data from its proprietary gamma sensory stimulation in patients with Alzheimer\u2019s Disease, at the 2022 Clinical Trials in Alzheimer’s Disease (CTAD), held November 29 – December 2, in San Francisco, CA.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe\u2019re excited to present data at CTAD 2022 showing our proprietary gamma sensory stimulation for a 6-month period reduced brain atrophy and preserved cognitive function in patients with Alzheimer\u2019s Disease,\u201d said Brent Vaughan, CEO, Cognito Therapeutics. \u201cOur clinical data has shown that our novel approach significantly slowed disease progression, preserving both brain function and brain volume in Alzheimer\u2019s patients. We believe the preservation of brain gray and white matter will have particularly important clinical implications, with broad applications in Alzheimer\u2019s and other neurological disorders.\u201d\n<\/p>\n

\nDetails of the poster presentation are below:\n<\/p>\n

\nPoster Title:<\/b> Increase in white matter volume and myelination after 6 months of 40Hz gamma sensory stimulation therapy in patients on Alzheimer\u2019s Disease spectrum\n<\/p>\n

\nPoster Number:<\/b> P076\n<\/p>\n

\nDate\/Time:<\/b> Thursday, December 1, 2022\n<\/p>\n

\nPresenter: <\/b>Aylin Cimenser, Ph.D., Senior Director of Data Science, Cognito Therapeutics\n<\/p>\n

\nCognito will also be hosting a reception at CTAD 2022:\n<\/p>\n

\nDate\/Time: Thursday, December 1, 6:00 \u2013 9:00 pm PT\n<\/p>\n

\nLocation: Vista Lounge, Hilton San Francisco Union Square (333 O’Farrell Street)\n<\/p>\n

\nRSVP to CTAD2022@cognitotx.com<\/a>.\n<\/p>\n

\nAbout Cognito Therapeutics\n<\/p>\n

\nCognito Therapeutics is a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic platform has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer\u2019s disease. Cognito has received FDA Breakthrough Device Designation for treatment of the cognitive and functional symptoms associated with Alzheimer’s disease in individuals diagnosed with mild to moderate Alzheimer\u2019s and expects to start pivotal studies in 2022. The company\u2019s technology is based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and optogenetics pioneer Ed Boyden at MIT. Cognito Therapeutics is based in Cambridge, MA. For more information, visit www.cognitotx.com<\/a>. Follow us on Twitter at @cognitotx.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia
\n
Kimberly Ha
\n
KKH Advisors
\n
917-291-5744
\n
kimberly.ha@kkhadvisors.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#CTAD2022—Cognito Therapeutics, a clinical-stage company pioneering disease-modifying therapeutic interventions for neurodegenerative diseases, announced today it has been selected to present clinical data from its proprietary gamma sensory stimulation in patients with Alzheimer\u2019s Disease, at the 2022 Clinical Trials in Alzheimer’s Disease (CTAD), held November 29 – December 2, in San Francisco, CA. \u201cWe\u2019re … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50265","6":"format-standard","7":"category-industry"},"yoast_head":"\nCognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer\u2019s Disease at 2022 CTAD Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer\u2019s Disease at 2022 CTAD Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–#CTAD2022—Cognito Therapeutics, a clinical-stage company pioneering disease-modifying therapeutic interventions for neurodegenerative diseases, announced today it has been selected to present clinical data from its proprietary gamma sensory stimulation in patients with Alzheimer\u2019s Disease, at the 2022 Clinical Trials in Alzheimer’s Disease (CTAD), held November 29 – December 2, in San Francisco, CA. \u201cWe\u2019re ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-31T12:02:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221031005048\/en\/1617395\/21\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%282%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer\u2019s Disease at 2022 CTAD Conference\",\"datePublished\":\"2022-10-31T12:02:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\\\/\"},\"wordCount\":384,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221031005048\\\/en\\\/1617395\\\/21\\\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%282%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\\\/\",\"name\":\"Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer\u2019s Disease at 2022 CTAD Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221031005048\\\/en\\\/1617395\\\/21\\\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%282%29.jpg\",\"datePublished\":\"2022-10-31T12:02:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221031005048\\\/en\\\/1617395\\\/21\\\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%282%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221031005048\\\/en\\\/1617395\\\/21\\\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%282%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer\u2019s Disease at 2022 CTAD Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer\u2019s Disease at 2022 CTAD Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer\u2019s Disease at 2022 CTAD Conference - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–#CTAD2022—Cognito Therapeutics, a clinical-stage company pioneering disease-modifying therapeutic interventions for neurodegenerative diseases, announced today it has been selected to present clinical data from its proprietary gamma sensory stimulation in patients with Alzheimer\u2019s Disease, at the 2022 Clinical Trials in Alzheimer’s Disease (CTAD), held November 29 – December 2, in San Francisco, CA. \u201cWe\u2019re ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-31T12:02:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221031005048\/en\/1617395\/21\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%282%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer\u2019s Disease at 2022 CTAD Conference","datePublished":"2022-10-31T12:02:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/"},"wordCount":384,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221031005048\/en\/1617395\/21\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%282%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/","url":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/","name":"Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer\u2019s Disease at 2022 CTAD Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221031005048\/en\/1617395\/21\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%282%29.jpg","datePublished":"2022-10-31T12:02:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221031005048\/en\/1617395\/21\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%282%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221031005048\/en\/1617395\/21\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%282%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-to-present-clinical-data-evaluating-gamma-frequency-neuromodulation-in-alzheimers-disease-at-2022-ctad-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer\u2019s Disease at 2022 CTAD Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50265"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50265\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}